DOACs–advances and limitations in real world
LH Lee - Thrombosis journal, 2016 - Springer
The group of new oral anticoagulants or NOACs, now termed direct oral anticoagulants or
DOACs, with their favourable results from large scale phase III clinical trials, represent a …
DOACs, with their favourable results from large scale phase III clinical trials, represent a …
Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic …
R Noviyani, S Youngkong, S Nathisuwan… - BMJ Evidence-Based …, 2022 - ebm.bmj.com
Objectives To assess cost-effectiveness of direct oral anticoagulants (DOACs) compared
with vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF) by pooling …
with vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF) by pooling …
Cost-effectiveness analysis of direct oral anticoagulants vs. vitamin K antagonists in the elderly with atrial fibrillation: insights from the evidence in a real-world setting
Y Wu, C Zhang, ZC Gu - Frontiers in Cardiovascular Medicine, 2021 - frontiersin.org
Background: In the clinical setting, the economic benefits of direct oral anticoagulants
(DOACs) in elderly patients with atrial fibrillation (AF) remain unclear. This study aimed to …
(DOACs) in elderly patients with atrial fibrillation (AF) remain unclear. This study aimed to …
Methods for economic evaluations of novel oral anticoagulants in patients with atrial fibrillation: a systematic review
Y Li, P Chen, X Wang, Q Peng, S Xu, A Ma… - Applied Health Economics …, 2024 - Springer
Background Atrial fibrillation (AF) is a severe epidemiological and public health concern
among the elderly population worldwide, with substantial economic and social burdens …
among the elderly population worldwide, with substantial economic and social burdens …
Cost Effectiveness of Strategies to Manage Atrial Fibrillation in Middle-and High-Income Countries: A Systematic Review
Background Atrial fibrillation (AF) remains the most common form of cardiac arrhythmia.
Management of AF aims to reduce the risk of stroke, heart failure and premature mortality via …
Management of AF aims to reduce the risk of stroke, heart failure and premature mortality via …
Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin …
F Laliberté, M Cloutier, C Crivera, WW Nelson… - Advances in …, 2015 - Springer
Introduction New target-specific oral anticoagulants may have benefits, such as shorter
hospital length of stay, compared to warfarin in patients with nonvalvular atrial fibrillation …
hospital length of stay, compared to warfarin in patients with nonvalvular atrial fibrillation …
[PDF][PDF] Cost-effectiveness of transcatheter aortic valve implantation in intermediate and low risk severe aortic stenosis patients in Singapore
Introduction: Singapore has the world's second most efficient healthcare system while
costing less than 5% GDP. It remains unclear whether transcatheter aortic valve implantation …
costing less than 5% GDP. It remains unclear whether transcatheter aortic valve implantation …
Cost-effectiveness modelling of novel oral anticoagulants incorporating real-world elderly patients with atrial fibrillation
YJ Zhao, L Lin, HJ Zhou, KT Tan, AP Chew… - International journal of …, 2016 - Elsevier
Abstract Background Novel oral anticoagulants (NOACs) expand the treatment options for
patients with atrial fibrillation (AF). Their benefits need to be weighed against the risk–benefit …
patients with atrial fibrillation (AF). Their benefits need to be weighed against the risk–benefit …
Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US
JD Miller, X Ye, GM Lenhart, AM Farr… - ClinicoEconomics …, 2016 - Taylor & Francis
Background Understanding the value of new anticoagulation therapies compared with
existing therapies is of paramount importance in today's cost-conscious and efficiency …
existing therapies is of paramount importance in today's cost-conscious and efficiency …
The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System Compared to Standard Management of Type 1 Diabetes in a Singapore Setting
D Gardner, M Lakkad, Z Qiu, Y Inoue… - Diabetes Technology …, 2024 - liebertpub.com
Background: Despite advances in technology, glycemic outcomes in people with type 1
diabetes (T1D) remain suboptimal. The MiniMed 780G (MM780G) advanced hybrid closed …
diabetes (T1D) remain suboptimal. The MiniMed 780G (MM780G) advanced hybrid closed …